BioSpace News Archive

Advancing a new era of treating sacroiliac (SI) joint pain with minimally invasive treatment, PainTEQ, in partnership with Evolve Restorative Center in Santa Rosa, Calif. and Celeri Health in Wilmington, Del., is leading a single-arm multicenter, prospective study exploring sacroiliac joint fusion using a posterior approach.

Orphazyme expects to submit MAA for arimoclomol for NPC to European Medicines Agency in the second half of 2020 Arimoclomol progressing through registrational trials in two additional indications - ALS and sIBM

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host the second webinar in its deep dive series discussing its therapeutic platforms and programs on Friday, July 24 at 10:00 am ET .

Chemomab Ltd ., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces that it has received all necessary regulatory approvals in the UK and Israel , to commence a Phase IIa clinical trial for CM-101 as treatment for Primary Sclerosing Cholan

Sorrel Medical (sorrelmedical.com), an Eitan Group Company, a developer and manufacturer of wearable drug delivery devices, today announced it has entered into a strategic partnership with one of the world’s leading pharmaceutical companies to advance the development and introduction of next-generation wearable drug delivery solutions.

The company announces its first patient enrolled and dosed in a Phase 1/2 clinical trial evaluating its novel IL12 cytokine, DF6002.

Angle Health, a Y Combinator-backed health insurance carrier, today announced that it has closed $4 million in a Series Seed funding round led by Blumberg Capital with participation from Y Combinator, Correlation Ventures, TSVC, Liquid 2 Ventures and several smaller funds and angels.

SLV213, a small molecule drug candidate, inhibits host cell cysteine proteases to block viral entry and has broad antiviral activity against coronaviruses, Ebola viruses, and paramyxoviruses SAN DIEGO--( BUSINESS WIRE )-- Selva Therapeutics, Inc. announced today that the company has raised $3 million in a Series A financing round from private investors. The proceeds of the financing will be used to rapidly advance SLV213 into clinical trials as a l

Exactech , a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, announced today the transition of its Equinoxe ® Stemless Shoulder to a 3D laser printing manufacturing process. The Stemless Shoulder, a bone-conserving anatomic total shoulder prosthesis, is now being manufactured using direct metal printing with high precision lasers

Nexa3D, the maker of ultrafast stereolithography production 3D printers, and Henkel, a leading supplier of high impact functional additive materials, announced today the immediate commercial availability of xMED412, a polypropylene-like material that is ideal for manufacturing a variety of biocompatible, medical and wearable devices.